FY2026 EPS Estimates for MMSI Boosted by Barrington Research

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Stock analysts at Barrington Research increased their FY2026 earnings per share (EPS) estimates for shares of Merit Medical Systems in a research report issued on Monday, December 23rd. Barrington Research analyst M. Petusky now expects that the medical instruments supplier will earn $4.28 per share for the year, up from their prior forecast of $4.25. Barrington Research currently has a “Outperform” rating and a $114.00 target price on the stock. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share.

Merit Medical Systems (NASDAQ:MMSI) last released its earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.80 by $0.06. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The company had revenue of $339.85 million during the quarter, compared to the consensus estimate of $334.60 million. During the same quarter in the previous year, the firm earned $0.75 EPS. The company’s revenue was up 7.8% on a year-over-year basis.

Several other equities research analysts also recently weighed in on the stock. Bank of America upped their price objective on shares of Merit Medical Systems from $92.00 to $103.00 and gave the stock a “neutral” rating in a report on Monday, September 16th. Robert W. Baird upped their price target on Merit Medical Systems from $107.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Needham & Company LLC reissued a “buy” rating and issued a $109.00 price target on shares of Merit Medical Systems in a research note on Thursday, October 31st. StockNews.com downgraded shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a research note on Sunday, November 3rd. Finally, Piper Sandler reiterated an “overweight” rating and set a $110.00 target price (up from $100.00) on shares of Merit Medical Systems in a research report on Monday, September 9th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Merit Medical Systems presently has an average rating of “Moderate Buy” and an average target price of $105.60.

Merit Medical Systems Trading Up 0.5 %

Merit Medical Systems stock opened at $98.08 on Wednesday. The company has a market cap of $5.72 billion, a P/E ratio of 48.08, a PEG ratio of 2.55 and a beta of 0.84. The firm’s 50-day moving average is $100.79 and its 200-day moving average is $94.04. Merit Medical Systems has a 1 year low of $70.70 and a 1 year high of $108.07. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36.

Insider Transactions at Merit Medical Systems

In other news, CFO Raul Jr. Parra sold 29,646 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $98.02, for a total value of $2,905,900.92. Following the sale, the chief financial officer now directly owns 16,361 shares in the company, valued at $1,603,705.22. The trade was a 64.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director F. Ann Millner sold 12,500 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.55, for a total transaction of $1,269,375.00. Following the completion of the sale, the director now owns 32,391 shares of the company’s stock, valued at approximately $3,289,306.05. This represents a 27.85 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Merit Medical Systems

Several hedge funds have recently bought and sold shares of the stock. Tidal Investments LLC grew its position in shares of Merit Medical Systems by 1.0% during the 3rd quarter. Tidal Investments LLC now owns 10,398 shares of the medical instruments supplier’s stock worth $1,028,000 after purchasing an additional 104 shares in the last quarter. American Century Companies Inc. increased its stake in Merit Medical Systems by 2.9% during the 2nd quarter. American Century Companies Inc. now owns 4,216 shares of the medical instruments supplier’s stock worth $362,000 after acquiring an additional 118 shares during the period. Xponance Inc. raised its holdings in Merit Medical Systems by 4.9% in the 2nd quarter. Xponance Inc. now owns 3,621 shares of the medical instruments supplier’s stock valued at $311,000 after acquiring an additional 170 shares in the last quarter. Glenmede Trust Co. NA lifted its position in shares of Merit Medical Systems by 0.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 28,637 shares of the medical instruments supplier’s stock valued at $2,830,000 after acquiring an additional 170 shares during the period. Finally, Captrust Financial Advisors grew its holdings in shares of Merit Medical Systems by 2.6% during the 3rd quarter. Captrust Financial Advisors now owns 7,440 shares of the medical instruments supplier’s stock worth $735,000 after purchasing an additional 187 shares in the last quarter. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.